Oragenics, Inc.(NYSE Amex Equities : OGEN)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||2.23%||8.71||0.7%||$608.86m|
|REGN||Regeneron Pharmaceuticals, Inc.||-0.20%||651.88||2.7%||$494.43m|
|GILD||Gilead Sciences, Inc.||0.39%||71.61||1.0%||$434.34m|
|VRTX||Vertex Pharmaceuticals, Inc.||0.64%||188.30||1.9%||$241.59m|
|ISEE||IVERIC bio, Inc.||1.59%||16.62||0.0%||$194.78m|
|LIFE||aTyr Pharma, Inc.||0.49%||10.31||3.2%||$144.19m|
|EXAS||EXACT Sciences Corp.||5.22%||108.15||18.1%||$135.69m|
Oragenics, Inc. is a biopharmaceutical company, which focuses on the development of novel antibiotics and treatments against infectious disease and oral mucositis. Its technology and pipeline is comprised of antibiotics and genetically engineered bacterial strains. The company was founded by Jeffrey D. Hillman and Robert T. Zahradnik in November 1996 and is headquartered in Tampa, FL.